These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23542171)

  • 1. CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis.
    Wong CH; Wu Z; Yu Q
    Oncogene; 2014 Mar; 33(10):1249-57. PubMed ID: 23542171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.
    Tan J; Zhuang L; Jiang X; Yang KK; Karuturi KM; Yu Q
    J Biol Chem; 2006 Apr; 281(15):10508-15. PubMed ID: 16476732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
    Shats I; Gatza ML; Liu B; Angus SP; You L; Nevins JR
    Cancer Res; 2013 Oct; 73(19):6056-67. PubMed ID: 23966291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
    Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
    Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.
    Wang Y; Alla V; Goody D; Gupta SK; Spitschak A; Wolkenhauer O; Pützer BM; Engelmann D
    Nucleic Acids Res; 2016 Jan; 44(1):117-33. PubMed ID: 26350215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
    Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
    BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E2F1 regulates p53R2 gene expression in p53-deficient cells.
    Qi JJ; Liu L; Cao JX; An GS; Li SY; Li G; Jia HT; Ni JH
    Mol Cell Biochem; 2015 Jan; 399(1-2):179-88. PubMed ID: 25312903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells.
    Cao QF; Qian SB; Wang N; Zhang L; Wang WM; Shen HB
    Cancer Biother Radiopharm; 2015 Mar; 30(2):87-93. PubMed ID: 25760728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E2F1-mediated apoptosis as a target of cancer therapy.
    Wu Z; Yu Q
    Curr Mol Pharmacol; 2009 Jun; 2(2):149-60. PubMed ID: 20021455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of E2F1 function by the nuclear corepressor KAP1.
    Wang C; Rauscher FJ; Cress WD; Chen J
    J Biol Chem; 2007 Oct; 282(41):29902-9. PubMed ID: 17704056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.
    Ben Shachar B; Feldstein O; Hacohen D; Ginsberg D
    Mol Cancer Res; 2010 Mar; 8(3):363-72. PubMed ID: 20197383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B.
    Paik JC; Wang B; Liu K; Lue JK; Lin WC
    J Biol Chem; 2010 Feb; 285(9):6348-63. PubMed ID: 20040599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression.
    Wu ZL; Zheng SS; Li ZM; Qiao YY; Aau MY; Yu Q
    Cell Death Differ; 2010 May; 17(5):801-10. PubMed ID: 19893569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
    Díaz-Núñez M; Díez-Torre A; De Wever O; Andrade R; Arluzea J; Silió M; Aréchaga J
    BMC Cancer; 2016 Aug; 16(1):667. PubMed ID: 27549189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.